Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 14/20 | 0.42 |
| ▸ | PPARA | Q07869 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12469961 | 0.89 | PPARA (0.48) | NOTUMPPARATSHR | |
| SCHEMBL28394924 | 0.73 | NOTUM (0.50) | NOTUMTSHRTLR8KDM4E | |
| SCHEMBL12906161 | 0.72 | NOTUM (0.59) | NOTUMTSHRMAPTTLR8KDM4E | |
| SCHEMBL5507183 | 0.70 | PPARA (0.40) | PPARA | |
| SCHEMBL8742299 | 0.70 | PPARA (0.40) | PPARA | |
| SCHEMBL28379479 | 0.67 | NOTUM (0.39) | NOTUMTSHRMAPTTLR8KDM4E | |
| SCHEMBL6306433 | 0.67 | NOTUM (0.39) | NOTUMTSHRMAPTTLR8ALDH1A1 | |
| SCHEMBL25144989 | 0.65 | NOTUM (0.44) | NOTUMTSHRMAPTKDM4EALDH1A1 | |
| SCHEMBL8426897 | 0.65 | PPARA (0.40) | PPARA | |
| SCHEMBL24922497 | 0.64 | TSHR (0.40) | NOTUMTSHRMAPTKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6407098-B1 | 3-(CARBOXIMINO)-1,4,2-OXATHIAZINE DERIVATIVES; PESTICIDES | BAYER AKTIENGESELLSCHAFT (DE) | 2002-06-18 | — | — | US | claimed |
| EP-0645378-B1 | Condensed seven- or eight-membered heterocyclic compounds useful as squalene synthetase inhibitors | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2000-08-23 | — | — | EP | claimed |
| US-20230331734-A1 | NOVEL SPIROPYRROLIDINE DERIVED ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2023-10-19 | — | — | US | disclosed |
| US-11377450-B2 | Functionalized heterocycles as antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2022-07-05 | — | — | US | disclosed |
| US-20210115060-A1 | FUNCTIONALIZED HETEROCYCLES AS ANTIVIRAL AGENTS | ENANTA PHARM INC (US) | 2021-04-22 | — | — | US | disclosed |
| EP-2797941-A1 | PREPARATION OF HETEROLEPTIC METAL COMPLEXES | Solvay SA (BE) | 2014-11-05 | — | — | EP | disclosed |
| EP-1511724-B1 | Process for the preparation of thioalkylamine derivatives | BAYER CROPSCIENCE AG (DE) | 2014-04-30 | — | — | EP | disclosed |
| WO-2013098189-A1 | PREPARATION OF HETEROLEPTIC METAL COMPLEXES | SOLVAY SA (BE) | 2013-07-04 | — | — | WO | disclosed |
| WO-2011135276-A1 | 3, 3 -DISUBSTITUTED- ( 8 - AZA - BICYCLO [3.2.1] OCT- 8 - YL) -[5- (1H - PYRAZOL - 4 -YL) -THIOPHEN-3 -YL] METHANONES AS INHIBITORS OF 11 (BETA) -HSD1 | THE UNIVERSITY OF EDINBURGH (GB) | 2011-11-03 | — | — | WO | disclosed |
| US-20070232538-A1 | Uses of polypeptides | TAKEDA PHARMACEUTICAL COMPANY, LTD (JP) | 2007-10-04 | — | — | US | disclosed |
| US-6160072-A | Process for polymerizing tactioselective polyolefins in condensed phase using titanocenes | MONTELL TECHNOLOGY COMPANY BV (NL) | 2000-12-12 | — | — | US | disclosed |
| EP-0842163-B1 | BENZENE DERIVATIVES WITH A HETEROCYCLIC GROUP | BASF AG (DE) | 1999-11-03 | — | — | EP | disclosed |
| US-5739166-A | ALKYLSULFONYL OR AMINOSULFONYL SUBSTITUTED AROMATIC COMPOUNDS AS NON-STEROIDAL ANTIINFLAMMATORY AGENT | G.D. SEARLE & CO. (US) | 1998-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11377450-B2 | Functionalized heterocycles as antiviral agents | HCCS, HAVCR2, HDGF | NOTUM 3255/4885PPARA 1956/4885TSHR 3380/4885 |
| US-20230331734-A1 | NOVEL SPIROPYRROLIDINE DERIVED ANTIVIRAL AGENTS | ACE, PKD1, ACE2 | NOTUM 175/4885PPARA 1272/4885TSHR 4021/4885 |
| US-20070232538-A1 | Uses of polypeptides | NPSR1, SCTR, GRPR | NOTUM 4517/4885PPARA 2460/4885TSHR 52/4885 |
| US-20210115060-A1 | FUNCTIONALIZED HETEROCYCLES AS ANTIVIRAL AGENTS | HCCS, HAVCR2, HDGF | NOTUM 3255/4885PPARA 1956/4885TSHR 3380/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.